CO6160296A2 - Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol - Google Patents
Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterolInfo
- Publication number
- CO6160296A2 CO6160296A2 CO08113909A CO08113909A CO6160296A2 CO 6160296 A2 CO6160296 A2 CO 6160296A2 CO 08113909 A CO08113909 A CO 08113909A CO 08113909 A CO08113909 A CO 08113909A CO 6160296 A2 CO6160296 A2 CO 6160296A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- cholesterol
- lipoprotein
- substituted
- density
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
- C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D233/16—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1.- Un compuesto de la fórmula (I)en donde: X es un enlace covalente, O o S; R1 y R2 se seleccionan independientemente del grupo que consiste de H, alquilo de C1-8, y alquilo de C1-8 sustituido, o R1, R2 y el átomo de carbono al cual están unidos juntos forman cicloalquilo de C3-7; R3 es H; R4 y R5 se seleccionan independientemente del grupo que consiste de H, halógeno, alquilo de C1-8, cicloalquilo de C3-7, cicloalquilo de C3-7-alquilo de C1-4, cicloalquiloxi de C3-7-alquilo de C1-4, alcoxi de C1-6-alquilo de C1-4, arilo de C6-10, heteroarilo, alquilo de C1-4 halógeno-sustituido, alquilo de C1-4 amino sustituido, alquilo de C1-4 arilo de C6-10 sustituido, alquilo de C1-4 ciano sustituido, y alquilo de C1-4 hidroxi sustituido; R6 y R7 se seleccionan independientemente del grupo que consiste de H, halógeno, alquilo de C1-3, alquilo de C1-3 halógeno sustituido, alcoxi de C1-3, y alcoxi de C1-3 halógeno-sustituido; n es 1; y Q se selecciona del grupo que consiste dey enantiómeros, diastereómeros, tautómeros, solvatos o sales farmacéuticamente aceptables de los mismos.2.- El compuesto de conformidad con la reivindicación 1, caracterizado además porque R1 y R2 se seleccionan independientemente del grupo que consiste de H y alquilo de C1-8, o R1, R2 y el átomo de carbono al cual están unidos juntos forman cicloalquilo de C3-5.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79300106P | 2006-04-18 | 2006-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6160296A2 true CO6160296A2 (es) | 2010-05-20 |
Family
ID=38610435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO08113909A CO6160296A2 (es) | 2006-04-18 | 2008-10-24 | Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol |
Country Status (30)
Country | Link |
---|---|
US (2) | US7678786B2 (es) |
EP (1) | EP2010289B1 (es) |
JP (1) | JP5232771B2 (es) |
KR (1) | KR101472370B1 (es) |
CN (1) | CN101479008B (es) |
AR (1) | AR060489A1 (es) |
AT (1) | ATE535282T1 (es) |
AU (1) | AU2007237928B2 (es) |
BR (1) | BRPI0711695A2 (es) |
CA (1) | CA2649700C (es) |
CO (1) | CO6160296A2 (es) |
CR (1) | CR10447A (es) |
EA (1) | EA016583B1 (es) |
EC (1) | ECSP088841A (es) |
ES (1) | ES2375754T3 (es) |
GT (1) | GT200800226A (es) |
HK (1) | HK1124797A1 (es) |
HN (1) | HN2008001559A (es) |
IL (1) | IL194850A (es) |
JO (1) | JO3444B1 (es) |
MX (1) | MX2008013534A (es) |
MY (1) | MY144637A (es) |
NO (1) | NO344334B1 (es) |
NZ (1) | NZ571998A (es) |
PE (1) | PE20080188A1 (es) |
TW (1) | TWI404712B (es) |
UA (1) | UA96150C2 (es) |
UY (1) | UY30288A1 (es) |
WO (1) | WO2007121432A2 (es) |
ZA (1) | ZA200809790B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
PL2240018T3 (pl) | 2008-01-04 | 2017-01-31 | Schabar Res Ass Llc | Kompozycja zawierająca środek przeciwbólowy i przeciwhistaminowy |
WO2009097995A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
CA2725680A1 (en) | 2008-05-30 | 2009-12-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US9051290B2 (en) | 2010-04-28 | 2015-06-09 | Leo Pharma A/S | Biaryl phosphodiesterase inhibitors |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
CN104086528A (zh) | 2010-07-15 | 2014-10-08 | 拜耳知识产权有限责任公司 | 作为杀虫剂的新杂环化合物 |
CN103298469A (zh) | 2010-08-31 | 2013-09-11 | 首尔大学校产学协力财团 | PPARδ激动剂的胎儿重编程的用途 |
US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013124382A1 (en) | 2012-02-24 | 2013-08-29 | Nestec S.A. | Peltatin for use in the treatment of cardiovascular disorders |
WO2013124380A1 (en) | 2012-02-24 | 2013-08-29 | Nestec S.A. | Peltatin for the treatment of chronic inflammatory disorders |
WO2013124381A1 (en) | 2012-02-24 | 2013-08-29 | Nestec S.A. | Peltatin for use in the treatment of metabolic disorders |
WO2014152809A2 (en) * | 2013-03-14 | 2014-09-25 | The University Of Toledo | Analogs of pparo and 20-oh-pge2, and methods of using the same |
WO2016057322A1 (en) | 2014-10-08 | 2016-04-14 | Salk Institute For Biological Studies | Ppar agonists and methods of use thereof |
US20210145775A1 (en) * | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Treatment of intestinal barrier dysfunction and associated diseases |
US11324727B2 (en) | 2020-07-15 | 2022-05-10 | Schabar Research Associates, Llc | Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn |
EP4181912A1 (en) | 2020-07-15 | 2023-05-24 | Schabar Research Associates LLC | Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2460689C3 (de) * | 1974-12-20 | 1980-06-26 | Klinge Pharma Gmbh & Co, 8000 Muenchen | 13-disubstituierte Propanol-(2)-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US4125732A (en) * | 1977-05-06 | 1978-11-14 | American Cyanamid Company | 2-Aryloxy-2-(phenoxyalkoxy)phenyl acetic acid and esters |
DE3026924A1 (de) | 1980-07-16 | 1982-02-18 | Klinge Pharma GmbH & Co, 8000 München | 1,3-diphenoxypropan-2-ol-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
DE3028776A1 (de) | 1980-07-29 | 1982-02-25 | Klinge Pharma GmbH & Co, 8000 München | Neue 1,3-diphenoxypropan-2-on-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
DE3169761D1 (en) | 1981-01-09 | 1985-05-09 | Fisons Plc | Phenoxy- and thiophenoxy compounds, methods for their preparation and pharmaceutical formulations containing them |
JPS58177934A (ja) | 1982-04-13 | 1983-10-18 | Takeda Chem Ind Ltd | ベンゾキノン誘導体 |
DE3366107D1 (en) | 1982-09-30 | 1986-10-16 | Merck Frosst Canada Inc | Leukotriene antagonists, their production, and compositions containing them |
US4820867A (en) | 1983-04-21 | 1989-04-11 | Merck Frosst Canada, Inc. | Phenoxypropoxy halophenylacetic acids as leukotriene antagonists |
US4513006A (en) * | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
JPS61268651A (ja) | 1985-05-23 | 1986-11-28 | Takeda Chem Ind Ltd | フエニル酢酸誘導体およびその製造法 |
EP0204349A3 (de) | 1985-06-01 | 1990-01-03 | Dr. Karl Thomae GmbH | Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
JPH0714910B2 (ja) | 1988-12-13 | 1995-02-22 | 塩野義製薬株式会社 | 安定な結晶性の塩およびそれを含有するトロンボキサン受容体拮抗剤 |
US5487008A (en) * | 1990-04-20 | 1996-01-23 | The Regents Of The University Of Michigan | Method and system for detecting the misfire of a reciprocating internal combustion engine in frequency domain |
CA2092152A1 (en) * | 1992-03-23 | 1993-09-24 | Azuma Igarashi | Phenoxyacetic acid compounds and medical preparations containing them |
US5726165A (en) * | 1994-07-29 | 1998-03-10 | Smithkline Beecham P.L.C. | Derivatives of 4-(2-aminoethyl)phenoxymethyl-phosphonic and -phosphinic acid and pharmaceutical and veterinary uses therefor |
ATE293963T1 (de) | 1996-02-02 | 2005-05-15 | Merck & Co Inc | Verfahren zur behandlung von diabetes und verwandter krankheitszustände. |
ATE245622T1 (de) | 1996-02-02 | 2003-08-15 | Merck & Co Inc | Antidiabetische mittel |
JP3268242B2 (ja) | 1996-11-14 | 2002-03-25 | 三共株式会社 | 縮合複素環化合物を含有する医薬 |
DE69840510D1 (de) | 1997-07-24 | 2009-03-12 | Astellas Pharma Inc | Medizinische zusammensetzungen mit cholesterin erniedrigender wirkung |
GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
GB0031107D0 (en) * | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
NZ529351A (en) | 2001-06-07 | 2006-01-27 | Lilly Co Eli | Modulators of peroxisome proliferator activated receptors |
PL366401A1 (en) | 2001-07-30 | 2005-01-24 | Novo Nordisk A/S | Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc. |
PT1424330E (pt) * | 2001-08-10 | 2011-12-22 | Nippon Chemiphar Co | Activador do receptor ä responsivo a proliferadores peroxissomais |
EA200400140A1 (ru) * | 2001-08-29 | 2004-08-26 | УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си | Пероральные противодиабетические агенты |
KR100933652B1 (ko) * | 2001-10-12 | 2009-12-23 | 닛뽕 케미파 가부시키가이샤 | 페록시좀 증식제 응답성 수용체 δ의 활성화제 |
ITRM20020014A1 (it) | 2002-01-15 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del |
EP1480957A1 (en) | 2002-03-01 | 2004-12-01 | Smithkline Beecham Corporation | Hppars activators |
US6875780B2 (en) * | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
GB0214149D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
EP1537076A1 (en) | 2002-09-05 | 2005-06-08 | Novo Nordisk A/S | Novel vinyl carboxylic acid derivatives and their therapeutical use |
AU2003273783C1 (en) | 2002-10-28 | 2010-08-12 | Vtv Therapeutics Llc | Novel compounds and their use as PPAR-modulators |
ES2344106T3 (es) | 2002-10-28 | 2010-08-18 | High Point Pharmaceuticals, Llc | Nuevos compuestos utiles en el tratamiento de enfermedades mediadas por ppar. |
EP1581491A1 (en) * | 2003-01-06 | 2005-10-05 | Eli Lilly And Company | Indole derivatives as ppar modulators |
US7384965B2 (en) * | 2003-01-06 | 2008-06-10 | Eli Lilly And Company | Fused heterocyclic derivatives as PPAR modulators |
PL378110A1 (pl) | 2003-02-14 | 2006-03-06 | Biogen Idec Ma Inc. | Kaseta ekspresyjna i wektor do przejściowej albo stabilnej ekspresji egzogennych cząsteczek |
PA8594401A1 (es) * | 2003-02-21 | 2004-09-16 | Pfizer | Acidos carboxilicos de heteroarilo condensado como agonista del ppar |
US7244763B2 (en) * | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
US6987118B2 (en) * | 2003-05-21 | 2006-01-17 | Pfizer Inc. | Tetrahydroisoquinoline derivatives as PPAR-alpha activators |
JP2007502815A (ja) | 2003-08-20 | 2007-02-15 | イーライ リリー アンド カンパニー | Ppar調節因子 |
EA009119B1 (ru) * | 2003-09-19 | 2007-10-26 | Янссен Фармацевтика Н. В. | 4-((феноксиалкил)тио)феноксиуксусные кислоты и аналоги |
ES2378435T3 (es) * | 2003-09-19 | 2012-04-12 | Janssen Pharmaceutica N.V. | �?cidos 4-((fenoxialquil)tio)-fenoxiacéticos y análogos |
WO2005041959A1 (en) | 2003-10-31 | 2005-05-12 | Janssen Pharmaceutica N.V. | Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (ppar) dual agonists |
WO2005060958A1 (en) * | 2003-12-19 | 2005-07-07 | Kalypsys, Inc. | (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes |
TW200538118A (en) | 2004-04-21 | 2005-12-01 | Schering Corp | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists |
EP1749000A4 (en) * | 2004-05-25 | 2009-12-30 | Metabolex Inc | BICYCLIC SUBSTITUTED TRIAZOLE AS PPAR MODULATORS AND METHOD FOR THE PRODUCTION THEREOF |
BRPI0512951A (pt) * | 2004-07-01 | 2008-04-15 | Hoffmann La Roche | compostos, processo para sua fabricação, composições farmacêuticas contendo os mesmos, uso e método para tratamento e/ou prevenção de doenças que são moduladas pelos agonistas de ppar(delta) e/ou ppar(alpha) |
CN101018790A (zh) * | 2004-09-11 | 2007-08-15 | 塞诺菲-安万特德国有限公司 | 7-氮杂吲哚以及其用作ppar激动剂的应用 |
MY145712A (en) * | 2004-09-15 | 2012-03-30 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
MY147518A (en) | 2004-09-15 | 2012-12-31 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
PE20060664A1 (es) | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
US20090012097A1 (en) * | 2006-01-30 | 2009-01-08 | Irm Llc | Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators |
GB0618963D0 (en) * | 2006-09-26 | 2006-11-08 | Ucl Business Plc | Formulations and composites with reactive fillers |
-
2007
- 2007-04-16 PE PE2007000463A patent/PE20080188A1/es active IP Right Grant
- 2007-04-16 UY UY30288A patent/UY30288A1/es active IP Right Grant
- 2007-04-17 BR BRPI0711695-0A patent/BRPI0711695A2/pt not_active IP Right Cessation
- 2007-04-17 CA CA2649700A patent/CA2649700C/en not_active Expired - Fee Related
- 2007-04-17 ES ES07760766T patent/ES2375754T3/es active Active
- 2007-04-17 AR ARP070101628A patent/AR060489A1/es active IP Right Grant
- 2007-04-17 JP JP2009506716A patent/JP5232771B2/ja not_active Expired - Fee Related
- 2007-04-17 MY MYPI20084161A patent/MY144637A/en unknown
- 2007-04-17 WO PCT/US2007/066772 patent/WO2007121432A2/en active Application Filing
- 2007-04-17 EP EP07760766A patent/EP2010289B1/en active Active
- 2007-04-17 TW TW096113405A patent/TWI404712B/zh not_active IP Right Cessation
- 2007-04-17 UA UAA200813306A patent/UA96150C2/ru unknown
- 2007-04-17 CN CN2007800226398A patent/CN101479008B/zh not_active Expired - Fee Related
- 2007-04-17 EA EA200870445A patent/EA016583B1/ru unknown
- 2007-04-17 JO JOP/2007/0139A patent/JO3444B1/ar active
- 2007-04-17 US US11/736,221 patent/US7678786B2/en active Active
- 2007-04-17 MX MX2008013534A patent/MX2008013534A/es active IP Right Grant
- 2007-04-17 AU AU2007237928A patent/AU2007237928B2/en not_active Ceased
- 2007-04-17 NZ NZ571998A patent/NZ571998A/en not_active IP Right Cessation
- 2007-04-17 AT AT07760766T patent/ATE535282T1/de active
-
2008
- 2008-10-17 HN HN2008001559A patent/HN2008001559A/es unknown
- 2008-10-21 GT GT200800226A patent/GT200800226A/es unknown
- 2008-10-22 IL IL194850A patent/IL194850A/en active IP Right Grant
- 2008-10-22 EC EC2008008841A patent/ECSP088841A/es unknown
- 2008-10-24 CO CO08113909A patent/CO6160296A2/es unknown
- 2008-11-14 KR KR1020087027903A patent/KR101472370B1/ko active IP Right Grant
- 2008-11-17 ZA ZA2008/09790A patent/ZA200809790B/en unknown
- 2008-11-18 NO NO20084847A patent/NO344334B1/no not_active IP Right Cessation
- 2008-11-18 CR CR10447A patent/CR10447A/es unknown
-
2009
- 2009-03-09 HK HK09102249.6A patent/HK1124797A1/xx not_active IP Right Cessation
-
2010
- 2010-01-19 US US12/689,335 patent/US8633184B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6160296A2 (es) | Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol | |
AR059184A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica | |
AR060807A1 (es) | Derivados de arilaminopiridina heteroaril - susutituidos como inhibidores de mek | |
CO6400139A2 (es) | Derivados de ciclopenta[c]pirool-2-carboxilatos, su preparación y su aplicación en terapéutica | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
CO6251260A2 (es) | Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c. | |
AR066169A1 (es) | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat | |
AR057350A1 (es) | Derivados de ciclohexanosulfonilo como inhibidores de glyt1 para tratar esquizofrenia. composiciones farmaceuticas | |
AR063142A1 (es) | Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen. | |
AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
CO6460743A2 (es) | Derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos, su preparación y su aplicación en terapéutica | |
CO6220967A2 (es) | Compuestos organicos y sus usos | |
CO5700774A2 (es) | Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa-1 | |
AR073136A1 (es) | Compuestos de pirrol | |
AR072428A1 (es) | Derivados de pirimidin nucleotidos inhibidores de polimerasas del virus de la hepatitis c (vhc), composiciones farmaceuticas que los contienen y metodo para prepararlos. | |
AR059621A1 (es) | Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1 | |
AR044715A1 (es) | Compuestos tipo amidas que inhiben la reabsorcion de las monoaminas | |
AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
AR056688A1 (es) | Derivados de la 4- amino - quinazolina su preparacion y su aplicacion en terapeutica | |
AR083953A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
AR057980A1 (es) | Derivados de la 1- amino-ftalazina sustituida, su preparacion y composicion farmaceutica | |
AR078321A1 (es) | Derivados de 2,4'-bipiridina como inhibidores de cinasa (cdk9) | |
AR075583A1 (es) | Derivados de isoxazol/o-piridina con eslabon etilo o etenilo | |
AR055431A1 (es) | Derivados del acido 4-amino-tieno[3,2-c]piridina-7-carboxilico | |
AR074862A1 (es) | Derivados de heterociclo biciclicos y sus metodos de uso |